Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$161.97 USD

161.97
575,208

+1.87 (1.17%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 6% (16 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

DaVita (DVA) Expands Operational Footprint Via New Agreement

by Zacks Equity Research

DaVita's (DVA) latest agreement is expected to serve a wider patient pool across Latin America.

Edwards (EW) Gains From RESILIA's Global Adoption, TAVR Growth

by Zacks Equity Research

With the Critical Care spin-off, Edwards (EW) is looking to pursue growth in TAVR, TMTT and Surgical, as well as new investments in interventional heart failure technologies.

DaVita Inc. (DVA) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

DaVita HealthCare (DVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Stryker (SYK) Completes First Arthroplasty Surgery in Europe

by Zacks Equity Research

Stryker (SYK) completes its first shoulder arthroplasty surgery in Europe using its Blueprint Mixed Reality Guidance system, which aims to benefit shoulder arthroplasty surgeons.

DexCom's (DXCM) Stelo Glucose Biosensor Receives FDA Approval

by Zacks Equity Research

DexCom's (DXCM) Stelo receives FDA clearance, which makes it the first FDA-approved glucose biosensor to be available over the counter.

Haemonetics (HAE) Signs Agreement to Acquire Attune Medical

by Zacks Equity Research

Haemonetics' (HAE) acquisition of the privately held Attune Medical is likely to add the pioneering ensoETM device to its EP portfolio.

Here's Why You Should Add Ecolab (ECL) to Your Portfolio

by Zacks Equity Research

Ecolab's (ECL) focus on R&D raises optimism about the stock.

Lantheus' (LNTH) DEFINITY Approved by FDA for Pediatric Use

by Zacks Equity Research

Lantheus' (LNTH) receipt of the expanded indication for DEFINITY is likely to address unmet medical needs of pediatric patients.

Penumbra (PEN) Gains From Innovation, Mounting Costs Ail

by Zacks Equity Research

Penumbra (PEN) expects to materially increase both revenues and profitability in the company's international business in the next three years and beyond.

Here's Why Investors Should Retain Bruker (BRKR) Stock Now

by Zacks Equity Research

The strength of the BSI BioSpin and CALID groups bodes well for Bruker (BRKR).

What's in the Offing for Brainsway (BWAY) in Q4 Earnings?

by Zacks Equity Research

Brainsway's (BWAY) fourth-quarter 2023 performance is likely to have been impacted by the strong momentum across the entire business.

Here's Why You Should Retain CONMED (CNMD) Stock for Now

by Zacks Equity Research

CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.

Boston Scientific (BSX) Grows IC Business With New FDA Nod

by Zacks Equity Research

The AGENT DCB of Boston Scientific (BSX) is already available in Europe, parts of Asia Pacific and Latin America.

ICON (ICLR) Gains From Strategic Deals, New Innovations

by Zacks Equity Research

ICON (ICLR) continues to evolve its collaboration and delivery models, invest in technology, and enhance its project and program management capabilities.

Reasons to Add ShockWave Medical (SWAV) to Your Portfolio Now

by Zacks Equity Research

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.

QIAGEN (QGEN) Launches AI-Driven Biomedical Knowledge Base

by Zacks Equity Research

QIAGEN (QGEN) introduces a Biomedical KB-AI knowledge base to accelerate data-driven drug discovery.

GE HealthCare's (GEHC) New Launch to Enhance Precision Care

by Zacks Equity Research

GE HealthCare's (GEHC) latest innovations are likely to provide patient-centered care for a broad patient population in a variety of clinical settings.

Philips (PHG) Aids Diagnostic Imaging With Philips CT 5300

by Zacks Equity Research

Philips (PHG) introduces AI-enabled Philips CT 5300 X-ray CT system, expanding its diagnostic imaging portfolio.

Quest Diagnostics (DGX) Hurt by Lower Testing Sales, Competition

by Zacks Equity Research

Quest Diagnostics (DGX) faces intense competition, primarily from LabCorp as well as other commercial laboratories and hospitals.

Here's Why You Should Retain Omnicell (OMCL) Stock Now

by Zacks Equity Research

Investors are optimistic about Omnicell (OMCL) moving closer to achieving its vision of Autonomous Pharmacy.

Bruker (BRKR) Inks Definitive Agreement to Acquire ELITechGroup

by Zacks Equity Research

Bruker (BRKR) announces a share purchase agreement to acquire the molecular diagnostics innovator ELITechGroup.

Urmimala Biswas headshot

5 Best PEG-Based GARP Stocks for Investors

by Urmimala Biswas

Here are the five stocks that qualify our screening criteria ¿¿¿ RCL, DVA, F, FIS and ITRI.

Waters (WAT) Boosts LC Solutions Portfolio With New Software

by Zacks Equity Research

Waters (WAT) unveils HPLC CONNECT software, bolstering its liquid chromatography solutions portfolio.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

McKesson (MCK) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.